z-logo
open-access-imgOpen Access
Observation on the Curative Effect of Madopar Combined with Pramipexole in the Treatment of Parkinson’s Diseases
Author(s) -
Yongting Yu,
Min Yang,
Ruihui Chen,
Hongbing Chen
Publication year - 2017
Publication title -
advanced emergency medicine
Language(s) - English
Resource type - Journals
ISSN - 2315-456X
DOI - 10.18686/aem.v6.80
Subject(s) - pramipexole , dopamine , parkinson's disease , acetylcholine , dopaminergic , medicine , disease , neurotransmitter , levodopa , striatum , neuroscience , psychology , central nervous system
Parkinson’s disease is a common neurological degenerative disease in the elderly. The clinical manifestations are static tremor, increased muscle tone, slow movement, abnormal posture gait, and severe symptoms of loss of self-care. Parkinson’s disease has become a burden to not only patient, but also to his family and to the society. Normal human brain neurotransmitter dopamine and acetylcholine are in a balanced state, the two antagonism can maintain normal body function. The pathological changes of patients with Parkinson’s disease is degeneration and apoptosis of dopaminergic neurons in striatum, resulting in a significant reduction in dopamine levels, and thus lead to an imbalance in the effects of dopamine and acetylcholine, and a decrease in dopamine resistance to acetylcholine Parkinson’s disease symptoms. As such, this article will focus on the analysis of the Madopar and pramipexole in the treatment of Parkinson’s disease symptoms.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here